G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that predictable and demanding routine of deadlines and meetings has returned. You knew this was inevitable, yes? Well, to cope, perhaps you would like to join us for a cup of stimulation to fortify those nerve endings. Remember that no prescription is required. We are opting for vanilla macadamia nut, by the way. So time to get started. Here are some items of interest. Hope your day goes well and do stay in touch …

A GlaxoSmithKline (GSK) gene therapy for “bubble boy” disease was approved by the U.K.’s cost watchdog, despite a $700,000 price tag, The Telegraph tells us. The Strimvelis treatment is offered by only one hospital in the world, in Italy, and children will be flown to Milan for a one-off cure. The medicine improves overall survival compared with standard stem cell transplant therapy against adenosine deaminase deficiency, which is an inherited condition.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy